0D53 Stock Overview
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Financière de Tubize SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €92.60 |
| 52 Week High | €94.00 |
| 52 Week Low | €60.90 |
| Beta | 0.47 |
| 1 Month Change | 0.44% |
| 3 Month Change | 23.47% |
| 1 Year Change | 18.73% |
| 3 Year Change | 12.52% |
| 5 Year Change | 50.08% |
| Change since IPO | 289.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0D53 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.2% | 3.3% | 2.7% |
| 1Y | 18.7% | -3.7% | 0.3% |
Return vs Industry: 0D53 exceeded the UK Pharmaceuticals industry which returned -5.5% over the past year.
Return vs Market: 0D53 exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0D53 volatility | |
|---|---|
| 0D53 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 8.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0D53 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0D53's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1928 | n/a | Eric Nys | www.financiere-tubize.be |
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Financière de Tubize SA Fundamentals Summary
| 0D53 fundamental statistics | |
|---|---|
| Market cap | €4.12b |
| Earnings (TTM) | €88.15m |
| Revenue (TTM) | n/a |
46.7x
P/E Ratio0.0x
P/S RatioIs 0D53 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0D53 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €2.03m |
| Gross Profit | -€2.03m |
| Other Expenses | -€90.18m |
| Earnings | €88.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 1.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.4% |
How did 0D53 perform over the long term?
See historical performance and comparison